Clinical trials: Cancer Patients and Physical Activity
Breast Cancer
An Exercise Intervention for Breast Cancer Patients: Feasibility and Effectiveness (BEAT Cancer Trial; Pilot Study)
"Translation" of the current "basic science" information related to physical activity into patient intervention programs is needed. This translation is critical to providing benefit to the maximum number of patients.
- Trial name
- BEAT (NCT00721565)
- Testing
- Exercise Behavior Change
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Alabama at Birmingham
B-cell Malignancy
Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma
A single arm, open-label, dose-escalation study to evaluate the safety and clinical activity of ThisCART19 (Allogeneic CAR-T targeting CD19) in patients with relapsed and/or refractory non-Hodgkin's B cell lymphoma (r/r B-NHL).
- Trial name
- NCT05106907
- Testing
- ThisCART19 cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fundamenta Therapeutics, Ltd.
HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid…
- Trial name
- AVZO-023-1001 (NCT06998407)
- Testing
- AVZO-021, Fulvestrant, Letrozole
- Where
- 16 sites in United States
- Volunteers
- 380 people
- Sponsor
- Avenzo Therapeutics, Inc.
Mature B-cell Malignancies
Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies
The purpose of this study is to evaluate the safety and tolerability of BGB-11417 monotherapy, define the maximum tolerated dose (MTD) or maximum administered dose and the recommended Phase 2 dose (RP2D) of BGB-11417 monotherapy…
- Trial name
- NCT04883957
- Testing
- BGB-11417
- Where
- 11 sites in China
- Volunteers
- 64 people
- Sponsor
- BeiGene
Malignant Neoplasm
18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions
This clinical trial studies 18F-clofarabine positron emission tomography (PET)/computed tomography (CT) in imaging patients with cancer before and after treatment with a therapy that activates the patient's immune system…
- Trial name
- NCT02888301
- Testing
- Computed Tomography, Fluorine F 18 Clofarabine, Positron Emission Tomography
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Fatigue
Exercise for Breast Cancer Patients (EXCAP)
The purpose of this study is to examine if exercise helps improve cancer-related fatigue. Hypothesis: A structured home-based walking and progressive resistance exercise program will be efficacious in relieving cancer-related…
- Trial name
- NCT00851812
- Testing
- Exercise, Progressive walking and resistance exercise treatment
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- University of Rochester
Multiple Myeloma, Non-Hodgkin Lymphoma
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This is a Phase I open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of tiragolumab administered as a single agent or in combination with…
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma
- Trial name
- NCT04045028
- Testing
- Tiragolumab, Daratumumab/rHuPH20, Rituximab
- Where
- 14 sites in United States, South Korea
- Volunteers
- 41 people
- Sponsor
- Genentech, Inc.
Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma
Laboratory studies suggest that the study drug may stop cancer cells from growing by affecting an interaction between proteins in the cells referred to as cAMP-response element-binding protein and ß-catenin.
- Conditions
- Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT01764477
- Testing
- PRI-724
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Prism Pharma Co., Ltd.
Cysticercosis, Cysts
Brain Tissue Swelling and Seizure Activity in Inactive Cysticercosis
This study will examine what causes seizures in patients with cysticercosis (pork tapeworm infection). A better understanding of this could lead to improved methods of controlling or preventing seizures.
- Conditions
- Cysticercosis, Cysts, Seizures
- Trial name
- NCT00001912
- Where
- 2 sites in United States, Peru
- Volunteers
- 6 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acute Myeloid Leukemia, Multiple Myeloma
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
To assess safety and tolerability, describe the dose-limiting toxicities, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a…
- Conditions
- Acute Myeloid Leukemia, Multiple Myeloma, Diffuse Large B-cell Lymphoma
- Trial name
- NCT03106428
- Testing
- MEDI7247
- Where
- 14 sites in United States, France and 1 more
- Volunteers
- 67 people
- Sponsor
- MedImmune LLC
Multiple Myeloma
Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma
Assess the impact in outcome of the use of zoledronic acid in multiple myeloma.
- Trial name
- NCT01234129
- Testing
- zoledronic acid
- Where
- Mexico
- Volunteers
- 320 people
- Sponsor
- Instituto Mexicano del Seguro Social
Multiple Myeloma, Neoplasms
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
This is a phase 1/2, open label, study designed to assess the safety and clinical activity of different belantamab mafodotin doses in combination with daratumumab, lenalidomide and dexamethasone.
- Conditions
- Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell, Gammopathy, Monoclonal
- Trial name
- NCT05280275
- Testing
- Belantamab Mafodotin-Blmf, Daratumumab, Lenalidomide
- Where
- 2 sites in Greece
- Volunteers
- 36 people
- Sponsor
- Hellenic Society of Hematology
Neoplasms
A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin
This dose-escalating study consists of 3 parts (A, B and C) and will evaluate the safety, pharmacokinetics and efficacy of RO5479599, alone or in combination with cetuximab or erlotinib, in participants with metastatic and/or…
- Trial name
- NCT01482377
- Testing
- RO5479599, Cetuximab, Erlotinib
- Where
- 12 sites in Denmark, Netherlands and 2 more
- Volunteers
- 145 people
- Sponsor
- Hoffmann-La Roche
Cancer, Cancer, Metastatic
Digitally-Captured Step Counts for Evaluating Performance Status in Advanced Cancer Patients
The purpose of this study is to examine the relationships between objectively measured physical activity and provider-assessed and patient-reported functional outcomes in patients with advanced cancer.
- Conditions
- Cancer, Cancer, Metastatic, Neoplasms
- Trial name
- DigiSTEPS (NCT03757182)
- Testing
- Wearable activity monitor
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Cedars-Sinai Medical Center
Non-Small Cell Lung Cancer
A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer
This was a Phase II, open-label, single-arm, single-stage, multicenter trial in patients with relapsed non-small cell lung cancer (NSCLC), with the objective of assessing the activity of the combination of erlotinib and…
- Trial name
- PENGUIN (NCT00855894)
- Testing
- Pertuzumab, Erlotinib
- Where
- 10 sites in United States, Australia
- Volunteers
- 41 people
- Sponsor
- Genentech, Inc.
Lymphedema, Breast Cancer, Lymphedema of Upper Limb
Does Inclusion of Diaphragmatic Breathing Exercises in Complete Decongestive Therapy Provide Further Benefits in Patients With Breast Cancer Related Lymphedema
Complete decongestive therapy is proven to be effective in reducing lymphedema related symptoms such as swelling and pain. Breathing exercises, on the other hand, may also help managing lymphedema symptoms.
- Trial name
- NCT05754346
- Testing
- Complete Decongestive Therapy, Upper extremity exercises combined with diaphragmatic breathing exercises
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Izmir Bakircay University
Advanced Solid Tumor, Solid Tumor
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors.
- Trial name
- NCT05981703
- Testing
- BGB-26808, Tislelizumab, Chemotherapy
- Where
- 28 sites in United States, Australia and 2 more
- Volunteers
- 337 people
- Sponsor
- BeOne Medicines
Breast Cancer, Breast Surgery
Breathing Interventions for Postoperative Breast Surgery Patients
This randomized controlled trial aims to evaluate the effects of pranayama and pursed-lip breathing exercises on postoperative pain, anxiety, and vital signs in patients undergoing breast surgery.
- Conditions
- Breast Cancer, Breast Surgery, Postoperative Pain, Anxiety
- Trial name
- BREATH-RCT (NCT07449273)
- Testing
- Pranayama Breathing Exercise, Pursed-Lip Breathing Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 126 people
- Sponsor
- Ondokuz Mayıs University
Brain Stem Neoplasms, Glioma
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Background: IMC-A12 is an experimental substance designed to inhibit a protein called Type I Insulin-Like Growth Factor Receptor (IGF-1R), which can be found on cancer cells and can promote cancer growth.
- Conditions
- Brain Stem Neoplasms, Glioma, Pinealoma
- Trial name
- NCT01182883
- Testing
- IMC-A12, Temsirolimus
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer
Alectinib in Neo-adjuvant Treatment of Stage III NSCLC
Stage III NSCLC is a heterogeneous group of tumors with a wide spectrum of clinical presentations. Across this wide spectrum of heterogeneity, there is no single definitive therapeutic approach and the definition of the most…
- Trial name
- ALNEO (NCT05015010)
- Testing
- Alectinib
- Where
- 20 sites in Italy
- Volunteers
- 33 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.